Brief: Almirall Gets EMA Acceptance For Paediatric Ebglyss
20/07/2026 09:05
BRIEF-Almirall Gets EMA Acceptance For Paediatric Ebglyss July 20 (Reuters) - Almirall SA ALM.MC:
ANNOUNCES EMA (EUROPEAN MEDICINES AGENCY) ACCEPTANCE FOR FILING OF PAEDIATRIC REGISTRATION OF EBGLYSS (LEBRIKIZUMAB) IN ATOPIC DERMATITIS IN CHILDREN 6 MONTHS AND OLDER
LEBRIKIZUMAB MEETS CO-PRIMARY AND KEY SECONDARY ENDPOINTS IN ADORABLE-1 STUDY
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 567 69 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24